Intervention

Sacituzumab govitecan-hziy (SG)

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting1

Common conditions4

Lead sponsors shown1

Clinical trials

2 shown

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12

Study of Novel Treatment Combinations in Patients With Lung CancerNCT05633667 · 2023-03-16

ACTIVE_NOT_RECRUITING

Common conditions

Advanced or Metastatic Non-Small-Cell Lung Cancer1 Lung Cancer1 Resectable Non-Small-Cell Lung Cancer1 Triple Negative Breast Cancer1

Leading sponsors

Gilead Sciences2

Trial status mix

ACTIVE_NOT_RECRUITING1

RECRUITING1

Phase mix

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.